Highlights Oryzon Genomics S.A.

Equities

ORY

ES0167733015

Market Closed - BME Other stock markets 11:35:13 2024-06-28 EDT			5-day change	1st Jan Change
1.818 ^EUR	-0.22%		-3.61%	-3.71%

06-26	Oryzon Genomics, S.A. Announces Presentation of Final Data from Portico, Vafidemstat's Global Phase IIb Trial in Borderline Personal Disorder, at the 37th ECNP Annual Conference	CI
06-14	Oryzon Genomics S.A. Presents Preliminary Data from Ongoing Phase Ib Frida Trial with Iadademstat Plus Gilteritinib in Relapsed/Refractory Flt3-Mut Aml Patients At Eha-2024	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Oryzon Genomics, S.A. Announces Presentation of Final Data from Portico, Vafidemstat's Global Phase IIb Trial in Borderline Personal Disorder, at the 37th ECNP Annual Conference	06-26	CI
Oryzon Genomics S.A. Presents Preliminary Data from Ongoing Phase Ib Frida Trial with Iadademstat Plus Gilteritinib in Relapsed/Refractory Flt3-Mut Aml Patients At Eha-2024	06-14	CI
Oryzon Genomics S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-06	CI
Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat	04-22	CI
ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer	04-08	CI
Oryzon Genomics S.A. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-26	CI
Oryzon Genomics, S.A. Announces Topline Results from Phase IIb Portico Study of Vafidemstat in Borderline Personality Disorder	01-05	CI
Oryzon Genomics, S.A. Announces Last Patient Last Visit in Its Phase IIb Portico Study for Borderline Personality Disorder	11-07	CI
Oryzon Genomics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-27	CI
Oryzon Genomics, S.A. Presents Blinded Aggregated Safety Data from Vafidemstat's Ongoing Phase IIB Portico Trial in Borderline Personal Disorder	23-10-10	CI
Oryzon Genomics S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-24	CI
Oryzon Genomics, S.A. Reports New Preliminary Blinded Aggregate Safety Data from Its Ongoing Phase IIb Portico Trial	23-07-05	CI
Oryzon Genomics, S.A. Presents Positive Preclinical Data of Ory-4001 for the Treatment of Charcot-Marie-Tooth Disease Presented At the 2023 Peripheral Nerve Society Annual Meeting	23-06-21	CI
Oryzon Genomics, S.A. to Present Positive Preclinical Efficacy Data of ORY-4001 in Charcot-Marie-Tooth Disease At the 2023 Peripheral Nerve Society Annual Meeting	23-05-30	CI
Oryzon Genomics S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Oryzon Genomics, S.A. Announces Positive Results from Planned Interim Analysis of PORTICO, a Phase 2b Adaptive Trial in Borderline Personality Disorder	23-04-03	CI
Oryzon Announces First Patient in Frida, A Phase Ib Trial with Iadademstat in Relapsed Refractory Flt3-Mutant Acute Myeloid Leukemia Patients	23-03-15	CI
Oryzon Genomics, S.A. Announces Clinical Candidate Nomination of ORY-4001 for the Treatment of CNS Disorders	23-03-13	CI
Oryzon Genomics S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-17	CI
Oryzon Genomics S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Oryzon Genomics S.A.

Equities

ORY

ES0167733015

Highlights

Filters